Trial Search Results

Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

ECOG-ACRIN Cancer Research Group

Collaborator: Cancer and Leukemia Group B

Stanford Investigator(s):

Intervention(s):

  • Other: placebo
  • Drug: selenium

Phase:

Phase 3

Eligibility


RUN-IN PERIOD:

Inclusion Criteria:

   - Histologically confirmed, completely resected stage IA (pT1, N0) or IB (pT2, N0)
   non-small lung cancer (except carcinoid)*

      - Completion of treatment for stage I lung cancer within the past 6 to 36 months
      and currently disease free

      - At least one mediastinal lymph node sampled at resection NOTE: *Southwest
      Oncology Group (SWOG) and Cancer and Leukemia Group B (CALGB) patients must be
      T1, N0; CALGB patients may be T2, N0 provided disease was completely resected
      prior to June 1, 2001 and participation in CALGB 9633 was refused if offered

   - 18 years old and over

   - Eastern Cooperative Oncology Group performance status 0-1

   - Bilirubin no greater than upper limit of normal (ULN)

   - Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase
   (SGPT) no greater than ULN

   - Prior mineral, herbal, phytochemical, or vitamin supplementation allowed

   - Concurrent non-selenium containing mineral, herbal, phytochemical, or vitamin
   supplementation allowed if schedule and supplementation prior to study remains
   unchanged

Exclusion Criteria:

   - Evidence of new or recurrent lung cancer on chest x-ray within the past 8 weeks

   - Synchronous lung or non-lung lesions or metastasis, even if resectable

   - History of more than one primary lung cancer at any time

   - Concurrent or other prior cancer within the past 5 years except localized non-melanoma
   skin cancer

   - Prior or concurrent chemotherapy for recurrent lung cancer

   - Prior or concurrent radiotherapy for recurrent lung cancer

   - Concurrent surgery

   - Concurrent supplement(s) containing more than 50 micrograms of selenium

STUDY PHASE:

   - Free of disease

   - Consumed at least 75% of tablets during 4-week run-in period

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting